Market Overview

Aerie Pharmaceuticals Announces Appointment of Ami Bavishi as Director, Investor Relations and Vincent Santucci, Pharm.D., as Director, Scientific Market Access

Share:

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retina diseases and other diseases of the eye, today announced
the appointment of Ami Bavishi as Director, Investor Relations,
reporting to Richard Rubino, Aerie's Chief Financial Officer. Ms.
Bavishi will drive all of Aerie's investor relations activities, and
joins Aerie from Burns McClellan, a public relations and investor
relations firm with which Aerie will maintain an ongoing relationship.
Aerie also announced the appointment of Vincent Santucci, Pharm.D., as
Director, Scientific Market Access, reporting to Theresa Heah, M.D.,
M.B.A., Aerie's Vice President of Clinical Research, Medical and
Professional Affairs. Dr. Santucci previously held related positions at
Sanofi Genzyme and Celgene.

In connection with their acceptance of their respective positions as
Director, Investor Relations and Director, Scientific Market Access, the
appointees will collectively receive awards totaling 28,800 stock
options. These stock options will vest over 4 years, with 25% vesting on
the first anniversary of the hire date and the remainder vesting ratably
on each of the subsequent 36 monthly anniversaries of the hire date.
These awards were made outside of Aerie's stockholder-approved equity
incentive plan and were approved by the Company's independent directors
as inducements material to the appointees entering into employment with
the Company in reliance on NASDAQ Listing Rule 5635(c)(4), which
requires this public announcement.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery,
development and commercialization of first-in-class therapies for the
treatment of patients with open-angle glaucoma, retina diseases and
other diseases of the eye. Aerie's first product, Rhopressa®
(netarsudil ophthalmic solution) 0.02%, a once-daily eyedrop approved by
the U.S. Food and Drug Administration (FDA) for the reduction of
elevated intraocular pressure (IOP) in patients with open-angle glaucoma
or ocular hypertension, was launched in the United States in April 2018.
In clinical trials of Rhopressa®, the most common adverse
reactions were conjunctival hyperemia, cornea verticillata, instillation
site pain, and conjunctival hemorrhage. More information about Rhopressa®,
including the product label, is available at www.rhopressa.com.
Aerie's advanced-stage product candidate, RocklatanTM
(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a fixed-dose
combination of Rhopressa® and the widely-prescribed PGA
(prostaglandin analog) latanoprost, achieved its 3-month primary
efficacy endpoint in two Phase 3 registration trials, Mercury 1 and
Mercury 2, and also showed safety and efficacy throughout 12 months in
Mercury 1. Aerie submitted the RocklatanTM New Drug
Application (NDA) in May 2018 and, in July 2018, the FDA set the PDUFA
(Prescription Drug User Fee Act) goal date for the completion of the
FDA's review of the RocklatanTM NDA for March 14, 2019. Aerie
continues to focus on global expansion and the development of additional
product candidates and technologies in ophthalmology, including for wet
age-related macular degeneration and diabetic macular edema. More
information is available at www.aeriepharma.com.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. We may, in some cases, use terms such as "predicts,"
"believes," "potential," "proposed," "continue," "estimates,"
"anticipates," "expects," "plans," "intends," "may," "could," "might,"
"will," "should," "exploring," "pursuing" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things: our
expectations regarding the commercialization and manufacturing of
Rhopressa® and RocklatanTM or any future product
candidates, including the timing, cost or other aspects of the
commercial launch of Rhopressa® and RocklatanTM or
any future product candidates; our commercialization, marketing,
manufacturing and supply management capabilities and strategies; the
success, timing and cost of our ongoing and anticipated preclinical
studies and clinical trials for Rhopressa®, with respect to
regulatory approval outside of the United States or additional
indications, and RocklatanTM or any future product
candidates, including statements regarding the timing of initiation and
completion of the studies and trials; our expectations regarding the
effectiveness of Rhopressa®, RocklatanTM or any
future product candidates and results of our clinical trials; the timing
of and our ability to request, obtain and maintain FDA or other
regulatory authority approval of, or other action with respect to, as
applicable, Rhopressa® and RocklatanTM or any
future product candidates, including the expected timing of, and timing
of regulatory and/or other review of, filings for, as applicable,
Rhopressa® and RocklatanTM or any future product
candidates; the potential advantages of Rhopressa® and
RocklatanTM or any future product candidates; our plans to
pursue development of additional product candidates and technologies
within and beyond ophthalmology, including development of Rhopressa®
and RocklatanTM for additional indications and other
therapeutic opportunities; our plans to explore possible uses of our
existing proprietary compounds beyond glaucoma, including development of
our retina program; our ability to protect our proprietary technology
and enforce our intellectual property rights; and our expectations
regarding strategic operations, including our ability to in-license or
acquire additional ophthalmic products, product candidates or
technologies. By their nature, forward-looking statements involve risks
and uncertainties because they relate to events, competitive dynamics,
industry change and other factors beyond our control, and depend on
regulatory approvals and economic and other environmental circumstances
that may or may not occur in the future or may occur on longer or
shorter timelines than anticipated. We discuss many of these risks in
greater detail under the heading "Risk Factors" in the quarterly and
annual reports that we file with the Securities and Exchange Commission
(SEC). In particular, FDA approval of Rhopressa® does not
constitute FDA approval of RocklatanTM, and there can be no
assurance that we will receive FDA approval for RocklatanTM
or any future product candidates. FDA approval of Rhopressa®
also does not constitute regulatory approval of Rhopressa® in
jurisdictions outside the United States and there can be no assurance
that we will receive regulatory approval for Rhopressa® in
jurisdictions outside the United States. Our receipt of a Prescription
Drug User Fee Act (PDUFA) goal date notification for RocklatanTM
does not constitute FDA approval of the RocklatanTM New Drug
Application (NDA), and there can be no assurance that the FDA will
complete its review by the PDUFA goal date of March 14, 2019, that the
FDA will not require changes or additional data that must be made or
received before it will approve the NDA, if ever, or that the FDA will
approve the NDA. Forward-looking statements are not guarantees of future
performance and our actual results of operations, financial condition
and liquidity, and the development of the industry in which we operate
may differ materially from the forward-looking statements contained in
this press release. Any forward-looking statements that we make in this
press release speak only as of the date of this press release. We assume
no obligation to update our forward-looking statements whether as a
result of new information, future events or otherwise, after the date of
this press release.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com